CTOs on the Move

Ribon Therapeutics

www.ribontx.com

 
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ribontx.com
  • Building D, 99 Hayden Avenue Suite 100
    99 Hayden Avenue, MA USA 02421
  • Phone: 617.914.8700

Executives

Name Title Contact Details

Funding

Ribon Therapeutics raised $65M on 01/04/2019

Similar Companies

SeqOne Genomics

Introducing the most advanced platform for clinical genomic analysis… Solutions for each type of medical use Using data and machine learning to build a more accurate picture of each patient We are passionate about creating bioinformatic solutions that ...

Scifluor Life Sciences

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

MAIA Biotechnology

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs